Sugi Predict

Sugi Predict / Compounds / SCHEMBL156688

SCHEMBL156688

SCHEMBL156688

CC(C)(C)n1ncc2c(N)ncnc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PI4KA P42356 3/20 0.61
▸ PI4K2B Q8TCG2 3/20 0.61
▸ PI4K2A Q9BTU6 3/20 0.61
▸ PI4KB Q9UBF8 3/20 0.61
▸ XDH P47989 6/20 0.50
▸ KDM4E B2RXH2 4/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ EGFR P00533 3/20 0.49
▸ CYP1A2 P05177 3/20 0.49
▸ HSD17B10 Q99714 2/20 0.49
▸ CYP2C19 P33261 2/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ HTT P42858 3/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ BLM P54132 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ ABL1 P00519 5/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29773082 1.00 PI4KA (0.61) PI4KAPI4K2BPI4K2API4KBXDH
SCHEMBL22971112 0.86 PI4KA (0.57) PI4KAPI4K2BPI4K2API4KBXDH
SCHEMBL26658515 0.83 PI4KA (0.54) PI4KAPI4K2BPI4K2API4KBXDH
SCHEMBL22521559 0.80 CYP1A2 (0.47) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL22521558 0.79 ABL1 (0.45) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL4569746 0.79 ABL1 (0.45) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL130407 0.76 PI4KA (1.00) PI4KAPI4K2BPI4K2API4KBXDH
SCHEMBL24659480 0.75 CYP1A2 (0.39) PI4KAPI4K2BPI4K2API4KBXDH
SCHEMBL22704493 0.75 CYP1A2 (0.36) PI4KAPI4K2BPI4K2API4KBXDH
SCHEMBL19049958 0.74 XDH (0.41) PI4KAPI4K2BPI4K2API4KBXDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025137605-A1 COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR C4 THERAPEUTICS, INC. (US) 2025-06-26 — — WO disclosed
US-20230383296-A1 MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF ALIGOS THERAPEUTICS, INC. (US) 2023-11-30 — — US disclosed
US-11795192-B2 Antimicrobial compounds, compositions, and uses thereof Lakewood Amedex, Inc. (US) 2023-10-24 — — US disclosed
US-11795192-B2 Antimicrobial compounds, compositions, and uses thereof Lakewood Amedex, Inc. (US) 2023-10-24 — — US disclosed
US-11787833-B2 Modified cyclic dinucleoside compounds as sting modulators ALIGOS THERAPEUTICS, INC. (US) 2023-10-17 — — US disclosed
US-20230287034-A1 CYCLIC DINUCLEOTIDES AS STING AGONISTS JANSSEN BIOTECH INC (US) 2023-09-14 — — US disclosed
US-20230287034-A1 CYCLIC DINUCLEOTIDES AS STING AGONISTS JANSSEN BIOTECH INC (US) 2023-09-14 — — US disclosed
CN-110548032-B Application of pyrazolopyrimidine compound in preparation of medicines for preventing/treating tumors 四川大学华西医院 2023-05-05 — — CN disclosed
EP-3430017-B1 COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES UNIV CALIFORNIA (US) 2023-01-25 — — EP disclosed
EP-3430017-B1 COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES UNIV CALIFORNIA (US) 2023-01-25 — — EP disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 — — US disclosed
US-20100273776-A1 INHIBITION OF ALPHA-SYNUCLEIN TOXICITY FOLDRx PHARMACEUTICALS, INC (US) 2010-10-28 — — US disclosed
US-20100273776-A1 INHIBITION OF ALPHA-SYNUCLEIN TOXICITY FOLDRx PHARMACEUTICALS, INC (US) 2010-10-28 — — US disclosed
US-20100273776-A1 INHIBITION OF ALPHA-SYNUCLEIN TOXICITY FOLDRx PHARMACEUTICALS, INC (US) 2010-10-28 — — US disclosed
EP-1730148-A4 AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS ABBOTT LAB (US) 2009-08-19 — — EP disclosed
WO-2009062118-A2 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2009-05-14 — — WO disclosed
WO-2007126841-A2 INHIBITION OF ALPHA-SYNUCLEIN TOXICITY FOLDRX PHARMACEUTICALS, INC. (US) 2007-11-08 — — WO disclosed
EP-1730148-A2 AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS Abbott Laboratories (US) 2006-12-13 — — EP disclosed
US-20060025383-A1 Aminobenzoxazoles as therapeutic agents ABBOTT LABORATORIES 2006-02-02 — — US disclosed
WO-2005074603-A2 AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS ABBOTT LABORATORIES (US) 2005-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025383-A1 Aminobenzoxazoles as therapeutic agents ABL1, MAP3K19, MAP3K20 PI4KA 222/4885PI4K2B 391/4885PI4K2A 658/4885
US-20230287034-A1 CYCLIC DINUCLEOTIDES AS STING AGONISTS STING1, CGAS, IFNAR1 PI4KA 2386/4885PI4K2B 2341/4885PI4K2A 2482/4885
US-20100273776-A1 INHIBITION OF ALPHA-SYNUCLEIN TOXICITY SNCA, PARK7, PINK1 PI4KA 2787/4885PI4K2B 2581/4885PI4K2A 2680/4885
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING RAB1A, COPB1, GOLT1B PI4KA 2727/4885PI4K2B 1908/4885PI4K2A 1850/4885
US-11787833-B2 Modified cyclic dinucleoside compounds as sting modulators STING1, CGAS, IRF3 PI4KA 2127/4885PI4K2B 2225/4885PI4K2A 2155/4885
US-20230383296-A1 MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF GJA1, GAP43, GJB2 PI4KA 2139/4885PI4K2B 2271/4885PI4K2A 2166/4885
US-11795192-B2 Antimicrobial compounds, compositions, and uses thereof CAT, MPO, NISCH PI4KA 1930/4885PI4K2B 2372/4885PI4K2A 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.